A comparison of cilostazol and pentoxifylline for treating intermittent claudication

American Journal of Medicine

Volumn 109, Issue 7, 2000, Pages 523-530

  Dawson, David L ^a,h   Cutler, Bruce S ^b   Hiatt, William R ^c   Hobson II, Robert W ^d   Martin, John D ^e   Bortey, Enoch B ^f   Forbes, William P ^f   Strandness Jr , D Eugene ^g  

^a WILFORD HALL MEDICAL CENTER   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^e Annapolis MD ^*  (United States)

^f Otsuka America Pharmaceutical   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

^h NASA JOHNSON SPACE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CILOSTAZOL; PENTOXIFYLLINE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; INTERMITTENT CLAUDICATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREADMILL EXERCISE; TREATMENT OUTCOME; WALKING SPEED;

AGED; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EXERCISE TEST; FEMALE; HUMANS; INTERMITTENT CLAUDICATION; MALE; MIDDLE AGED; PENTOXIFYLLINE; SEVERITY OF ILLNESS INDEX; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; VASODILATOR AGENTS; WALKING;

EID: 0033754497     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(00)00569-6     Document Type: Article

References (22)

1. Prevalence of intermittent claudication and its effect on mortality
2. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: A critical review
3. Cilostazol has beneficial effects in treatment of intermittent claudication: Results from a multicenter, randomized, prospective, double-blind trial
4. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease
5. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication
6. A new pharmacological treatment for intermittent claudication: Results of a randomized, multicenter trial
7. Proposed design for a double blinded trial to evaluate medications for treatment of intermittent claudication
8. The evaluation of exercise performance in patients with peripheral vascular disease
9. Suggested standards for reports dealing with lower extremity ischemia
10. Evaluation of walking impairment by questionnaire in patients with peripheral arterial disease
11. Pentoxifylline and intermittent claudication: Review of clinical trials and cost-effectiveness analyses
12. Progressive versus single-stage treadmill tests for the evaluation of claudication
13. Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid, and ticlopidine on platelet functions ex vivo. Randomized, double-blind cross-over study
14. Hemodynamic effects of the antithrombotic drug cilostazol in chronic arterial occlusion in the extremities
15. Pentoxifylline efficacy in the treatment of intermittent claudication: Multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients
16. Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease
17. Drug treatment of intermittent claudication: A critical analysis of the methods and findings of published clinical trials, 1965-1985
18. Conservative management of intermittent claudication
19. Management of intermittent claudication with pentoxifylline: Meta-analysis of randomized controlled trials
20. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis
21. Management of peripheral arterial disease (PAD). TASC Working Group